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Abstract
To better understand Zaire ebolavirus (ZEBOV) circulation and transmission to humans, we conducted a large serological
survey of rural populations in Gabon, a country characterized by both epidemic and non epidemic regions. The survey
lasted three years and covered 4,349 individuals from 220 randomly selected villages, representing 10.7% of all villages in
Gabon. Using a sensitive and specific ELISA method, we found a ZEBOV-specific IgG seroprevalence of 15.3% overall, the
highest ever reported. The seroprevalence rate was significantly higher in forested areas (19.4%) than in other ecosystems,
namely grassland (12.4%), savannah (10.5%), and lakeland (2.7%). No other risk factors for seropositivity were found. The
specificity of anti-ZEBOV IgG was confirmed by Western blot in 138 individuals, and CD8 T cells from seven IgG+ individuals
were shown to produce IFN-c after ZEBOV stimulation. Together, these findings show that a large fraction of the human
population living in forested areas of Gabon has both humoral and cellular immunity to ZEBOV. In the absence of identified
risk factors, the high prevalence of ‘‘immune’’ persons suggests a common source of human exposure such as fruits
contaminated by bat saliva. These findings provide significant new insights into ZEBOV circulation and human exposure,
and raise important questions as to the human pathogenicity of ZEBOV and the existence of natural protective
immunization.
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Introduction
Ebolavirus (EBOV) and its close relative marburgvirus (MARV)
compose the Filoviridae family of viruses causing severe hemor-
rhagic fever (HF) in humans and non human primates [1]. The
EBOV genome is about 19 000 nucleotides long and consists of a
single strand of negative-sense RNA that encodes seven linearly
arranged gene products, in the following order: the nucleoprotein
(NP), VP35, VP40, glycoprotein, VP30, VP24, and the polymerase
(L). The genus Marburgvirus consists of a single species, while there
are five known species of Ebola-like-viruses that have different
geographic locations and case fatality rates, and about 32% to
41% of nucleotide sequence differences [2]. The species Reston
ebolavirus was first isolated from Asian cynomolgus monkeys from
the Philippines; it is pathogenic for non human primates but
apparently non pathogenic for humans [3,4]. Recently, Reston
ebolavirus was also isolated from domestic Philippino swine with a
severe respiratory syndrome and coinfected by porcine reproduc-
tive and respiratory syndrome virus [5]. The species Co ˆte d’Ivoire
ebolavirus has been associated with a single, non fatal human case,
in Ivory Coast in 1994 [6]. Sudan ebolavirus has caused four known
outbreaks, three in Sudan [7–9] and one in Uganda [10,11] with a
reported case fatality rate of around 50%. The latest species to be
discovered, Bundibugyo ebolavirus, was discovered in 2007 in
Uganda, where it was responsible for a large outbreak, with 116
confirmed cases and 30 deaths (case fatality rate 26%) [12]. Zaire
ebolavirus (ZEBOV) is the most pathogenic species, with reported
case fatality rates of up to 90%. ZEBOV has caused several
outbreaks in Central Africa, Democratic Republic of Congo
(DRC), Republic of Congo (RC) and Gabon [13–17]. North-east
Gabon experienced four outbreaks between 1994 and 2002, with a
total of 259 confirmed human cases and only 79 survivors (case
fatality rate: 69%).
Recently, significant advances have been made in our under-
standing of filovirus ecology. Antibodies and nucleotide sequences
specific for ZEBOV [18,19] have been detected in the liver and
spleen of three fruit bat species in Gabon and RC (Hypsignathus
monstrosus, Epomops franquetti, and Myonycteris torquata), and antibodies
and nucleotide sequences specific for MARV [20,21] have been
found in a fruit bat species in Gabon (Rousettus aegyptiacus) and in two
insectivorous bat species in DRC (Rhinolophus eloquens and Miniopterus
inflatus). More recently, MARV was isolated for the first time in
cave-dwelling Rousettus aegyptiacus in Uganda [22]. Together, these
findings raise the possibility that these bats might be a filovirus
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0reservoir, but the mechanism of primary ZEBOV transmission to
humans, potentially leading to outbreaks, remains unclear. The
Ebola hemorrhagic fever (EHF) outbreaks that occurred in Gabon
and RC between 2001 and 2003 were also associated with major
outbreaks among wild-living large mammals (especially chimpan-
zees and gorillas), devastating local animal populations [16,23,24].
The primary human cases involved hunters who became infected
after handling animal carcasses found in the forest [16]. Similarly,
the 1996 Mayibout outbreak in Gabon started among children who
handled a chimpanzee carcass [15]. A recent study showed that the
2007 Luebo outbreak in DRC was linked to massive fruit bat
migration, strongly suggesting for the first time that humans could
be infected directly by bats [25]. However, the source of most
EBOV and MARV outbreaks has not been identified.
It is generally accepted that ZEBOV is associated with a case
fatality rate of about 90%, but this may be an overestimate. First,
seven cases of asymptomatic infection were identified during the
1996 Booue ´ outbreak in Gabon [26]. Second, some ELISA-based
serosurveys [27] have shown high antibody prevalence rates among
populations living in areas where no cases of EHF have ever been
reported, suggesting that ZEBOV might also be capable of causing
mild illness or even asymptomatic infection in humans. The IgG
seroprevalence was 9.3% in villages located in the 1995 outbreak
areaaroundKikwit,DRC, where no EHFcaseswerereported [28].
Likewise, a seroprevalence of 13.2% was found in the Aka Pygmy
population of Central African Republic, where no ZEBOV
outbreaks have ever been reported [29]. These findings confirmed
those of older studies based on less-specific immunofluorescence
assaysthatshowedanantibodyprevalence ofaround10%inseveral
non epidemic parts of Africa [30–34]. In contrast, a more recent
survey showed a low anti-ZEBOV IgG prevalence (1.4%) among
979 people living in the northern region of Gabon that experienced
EHF outbreaks between 1994 and 1997 [35]. The authors deduced
that mild or asymptomatic EHF infection was possible but rare.
The source and significance of anti-ZEBOV IgG seropositivity
among people who have never had clinical signs of hemorrhagic
fever or who live in non epidemic areas are both unclear, but they
may have major implications for our understanding of the
epidemiology of ZEBOV of primary transmission to humans and
outbreaks. Wethereforeconducteda very largeserological survey of
ZEBOV exposure among rural populations of Gabon, a country
with both epidemic and non epidemic regions. The specificity of
ZEBOV-specific IgG was confirmed by western blot, and ZEBOV-
specific memory T cell responses were investigated for the first time.
Results
Survey Participation
We enrolled 4,349 individuals in 220 randomly selected villages
covering all the ecological regions of the country (Figure 1). Blood
samples and sociodemographic data were available for all 4,349
participants. All participants were $16 years old, and 2,227
(51.2%) females and 2,122 (48.4%) males participated. The
participants were located in the Forest (2,540 participants;
58.4% of the study population), Grassland (918; 21.1%), Savannah
(448; 10.3%) and Lakeland (443; 10.2%) regions. The Forest area
was subdivided into North-Eastern Forest (825; 19%), Interior
Forest (1,314; 30.2%) and Mountain Forest (401; 9.2%).
Cut-Off Calculation
The cut-off value for IgG positivity was determined by using a
negative control population of volunteers sampled in Marseille,
France in 2008. Nothing was known of ZEBOV circulation in the
area studied. It was therefore impossible to define a control
population with which to determine the OD distribution in
seronegative subjects: inclusion of seropositive subjects among the
controls would have undermined the validity of this distribution
and the determination of a valid cutoff. We therefore chose a more
rigorous approach, based on the choice of control subjects who
were almost certain to be seronegative, yielding a valid
‘‘background’’ OD distribution; we also chose a curve largely
covering this distribution and made a conservative choice of cutoff
(error risk below 1/1000 for the first ‘‘positive’’ value). The cutoff
was therefore based on a highly conservative approach. Finally,
the OD distribution of the Gabonese population sample showed a
strong excess of values in the range [0.05, 0.20] (relative to the
reference distribution), but, thanks to the use of a conservative
approach, these values were not considered as positive.
The distribution in the negative control population was centered
near 0 (mean 0.006, median 0.009), with a standard deviation of
0.071 (data not shown). This distribution can be surrounded in the
positive values by a negative exponential distribution (y=a*exp
(-35*(x-0.006))). The exponential distribution gave a better fit than
normal and gamma distributions. With this formal distribution, the
observed distribution of all ODs was under the curve and the
probability of an individual having an OD above 0.2 was less than
1%. A sample was considered positive when its adjusted OD was
above the cut-off (0.2 at 1:1600 dilution) and when the OD in the
viral antigen-coated well was twice as high as the OD in the
uninfected antigen-coated well. All samples were tested in duplicate.
ZEBOV-Specific IgG Seroprevalence and Regional
Distribution
The seroprevalence of ZEBOV-specific IgG in the study
population was 15.3% overall (Table 1), and varied significantly
Figure 1. Map of Gabonese villages (red circles) included in the
survey, according to the ecological region. Villages where
children ,16 years were specifically included in the study are indicated
by yellow circles. The overall prevalence of ZEBOV-specific IgG in each
ecological region is shown.
doi:10.1371/journal.pone.0009126.g001
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seroprevalence rate in the Forest region (19.4%) was significantly
higher than that found in the other regions (p,0.001). Similarly,
the seroprevalence rate in the Lakeland region (2.7%) was
significantly lower than that found in the other areas (p,0.001).
No significant difference was observed (p$0.3) between Savannah
(10.5%) and Grassland (12.4%) nor between the three types of
Forest area (p$0.4) (Table 1).
As shown in Table 2, no significant difference (p$0.9) in
seroprevalence was observed across villages where no ZEBOV
outbreaks had been reported (19.5%), villages hit by the 1996–
1997 outbreaks (20.2%), and villages hit by the 2001–02 outbreak
(18.3%).
Seroprevalence rates varied widely across neighboring villages
in each ecological region (Figure 2), ranging from 0% to 13.2% in
Lakeland, 0% to 16.1% in Savannah, 3.8% to 30.8% in
Grassland, and 5% to 33.3% in Forest.
Influence of Sociodemographic Characteristics on
ZEBOV-Specific IgG Seroprevalence
Because the seroprevalence rates varied across the ecological
areas, we examined the possible influence of sociodemographic
characteristics (Table 3). No correlation was found between the
seroprevalence rate and gender, age, hunting activity or contact
with specific forest animals in a given ecological area (Table 3).
The ‘hunting’ subgroup consisted of men who hunted frequently or
occasionally, and thus excluded females. The ‘contact with specific
forest animals’ subgroup included hunters, individuals who kept wild
animals as pets, those who butchered dead animals, and those who
cooked them.
The seroprevalence did not significantly vary with age (Table 3).
However, only individuals older than 21 years were included in
this analysis, owing to the small number of younger participants.
In order to evaluate the influence of age among individuals
younger than 21 years, we conducted a specific field study of
children living in six villages located in the north-east forest area.
We enrolled 395 children between 2 and 15 years old. The
seroprevalence rate was significantly lower in the 1–10 year age
group (8.7%; p=0.005) than in all the other age groups (Table 4).
The seroprevalence rates were 18.5% in the 11–20 year age group,
20.2% in the 21–30 year age group, 23.7% in the 31–40 year age
group, 20.1% in the 41–50 year group and 18.5% in the $51 year
group. The seroprevalence rates increased linearly with age below
15 years (Figure 3).
Detection of Specific Anti-ZEBOV IgG by Western Blot
To confirm the specificity of anti-ZEBOV IgG, 150 randomly
selected sera of the 667 positive samples were analyzed by western
blotting in denaturing conditions with purified ZEBOV antigens,
but technical problems meant that clear-cut results could not be
obtained for 12 of them. All 138 sera tested by western blot (about
21% of all the positive samples) reacted with at least one ZEBOV
protein. These selected sera represented a broad range of ODs and
a broad geographic area of Gabon. Depending on the individual,
IgG reactivity was directed against NP, VP40, VP35 VP24 and/or
sGP (Figure 4). In total, 76% of the 138 sera reacted to VP40, 56%
to NP, 36% to VP35 and 24% to sGP, while only one sample
reacted to VP24. The IgG reactivity of serum from two survivors
was also mainly directed to NP and VP40 (Figure 4).
ZEBOV-Specific T Lymphocyte Memory Responses
To detect ZEBOV-specific T cell memory responses in these
IgG+ individuals, intracellular levels of TNF-a and IFN-c were
determined in CD4+ and CD8+ T cell populations from seven
randomly selected IgG+ individuals. Positive gating for lympho-
cytes based on forward and side scatter was followed by
CD3+CD4+ and CD3+CD8+ gating, and specific populations
were further defined by using antibodies specific for CD8 and
CD4, respectively. Cytokine-positive cells were expressed as a
percentage of the corresponding lymphocyte subset.
With samples from IgG+ individuals and from three survivors of
ZEBOV infection, the percentage of circulating CD4+ T cells
producing IFN-c did not increase after PBMC stimulation (data
not shown). In contrast, with samples from the seven IgG+
individuals, the percentage of circulating CD8+ T cells producing
IFN-c was higher on day 2 or 3 of PBMC stimulation by iZEBOV
than after mock stimulation (Figure 5). This increase was noted on
day 2 in individuals #IgG+1, IgG+3 and IgG+4, and on day 3 in
Table 1. Prevalence of ZEBOV-specific IgG in Gabon
according to the ecological region.
N positive prevalence p value
All participants 4,349 667 15.3%
Lakeland area 443 12 2.7% ,0.001 ,0.001 ,0.001
Savannah area 448 47 10.5% ,0.001 0.3 referent
Grassland 918 114 12.4% ,0.001 referent
Forest aera 2,540 494 19.4% referent
Northern-Eastern 825 167 20.2%
Interior 1,314 242 18.4% 0.4
Mountains 401 85 21.2%
doi:10.1371/journal.pone.0009126.t001
Table 2. Prevalence of ZEBOV-specific IgG in Gabon
according to epidemic and non epidemic areas in Gabon.
Forest area N positive prevalence p value
Villages without outbreak 2,307 449 19.5% referent
Villages hit by 1996 outbreaks 129 26 20.2% 0.9
Villages hit by 2001 outbreak 104 19 18.3% 0.9
doi:10.1371/journal.pone.0009126.t002
Figure 2. Prevalence of ZEBOV-specific IgG in villages within
each ecological region. Each circle represents a group of two or
three neighboring villages.
doi:10.1371/journal.pone.0009126.g002
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responses were observed in individuals #IgG+1, IgG+2 and
IgG+3, with a 3-fold increase. Similar levels of IFN-c-producing
CD8+ T cells were observed in PBMC obtained from three
survivors of ZEBOV infection, after iZEBOV stimulation. By
contrast, no increase was observed with samples from the four
IgG-negative controls (Figure 5).
PBMC from one individual were stimulated with iZEBOV on
day 0 and again on day 6. The percentage of circulating IFN-c-
producing CD8+ T rose one day after each stimulation, i.e. on day
2 and day 7 (Figure 6). No increase in the percentage of TNF-a-
producing CD8+ or CD4+ T cells was observed with PBMC from
IgG+ individuals, although both CD8+ and CD4+ T cells from all
three survivors produced low levels of TNF-a on day 3 after
iZEBOV stimulation (data not shown).
Discussion
To our knowledge this is the largest human serological survey of
Ebola virus conducted to date. It lasted three years and covered
4,349 individuals in 220 randomly selected villages, representing
10.7% of all villages in Gabon. The overall seroprevalence of
ZEBOV-specific IgG was 15.3%, the highest rate ever found. The
seroprevalence was even higher in forested areas (representing L
of the total surface area of Gabon), reaching 19.4% overall and
33.8% in some villages. The lowest seroprevalence was found in
the Lakeland region (2.7%).
These results are consistent with previous studies showing
seroprevalence rates ranging from 1.8% to 21.3% [30–34].
However, these latter surveys used a poorly specific IFAT method
associated with frequent false-positive results [27]. Two recent
small serosurveys based on the same ELISA assay as that used here
showed elevated seroprevalence rates in some forested regions of
central Africa. For example, ZEBOV-specific IgG was found in
9.3% of 161 individuals living in unaffected villages near Kikwit, a
few weeks after the 1995 outbreak [28]. Likewise, a rate of 13.2%
was found among 190 Aka Pygmies in Central African Republic,
where ZEBOV outbreaks have never been reported [29].
However, these surveys involved only small numbers of individuals
and a low plasma dilution (1:400), and the specificity of ZEBOV
IgG was not confirmed in more specific tests such as western blot.
We used western blot, for the first time, to confirm the
specificity of ZEBOV IgG in 138 ELISA-positive samples selected
randomly from various regions of Gabon (about one in five of the
positive samples). As previously shown among survivors [36] and
Table 3. Prevalence of ZEBOV-specific IgG according to demographic characteristics in individuals aged $20 years, Gabon.
Forest Grassland Savannah Lakeland
N Pos (%) p value N Pos (%) p value N Pos (%) p value N Pos (%) p value
Male 1,181 248 (21%) 0,07 471 72 (15.3%) 0.01 191 25 (13.1%) 0.1 206 9 (4.4%) 0.09
Female 1,359 246 (18.1%) 447 42 (9.4%) 257 22 (8.6%) 237 3 (1.3%)
Age (years)
21–30 343 275 (19.6%) 0.4 122 14 (11.5%) 0.7 55 5 (9.1%) 0.9 70 3 (4.3%) 0.7
31–40 425 343 (19.3%) 157 17 (10.8%) 74 8 (10.8%) 82 3 (3.7%)
41–50 498 390 (21.7%) 197 29 (14.7%) 102 10 (9.8%) 72 2 (2.8%)
$51 1186 215 (18.1%) 404 51 (12.6%) 197 23 (11%) 209 4 (1.9%)
Hunting 775 163 (21%) 0,9 262 43 (16.4%) 0.5 128 14 (10.9%) 0.3 67 6 (8.9%) 0.07
No hunting 403 85 (21.1%) 209 29 (13.9%) 63 11 (17.5%) 135 3 (2.2%)
Contact with animals 2473 481 (19.4%) 0,9 ND ND ND
No contact with animals 67 13 (19.4%) ND ND ND
doi:10.1371/journal.pone.0009126.t003
Figure 3. Prevalence of ZEBOV-specific IgG according to age in
the north-eastern region of Gabon (green). The overall prevalence
of ZEBOV-specific IgG according to age is shown in brown.
doi:10.1371/journal.pone.0009126.g003
Table 4. Prevalence of ZEBOV-specific IgG according to age
in the north-eastern region of Gabon.
Northern-Eastern forest
Age (years) N Pos (%) p value
1–10 207 18 (8.7%) 0.005
11–20 232 43 (18.5%) 0.7
21–30 124 25 (20.2%)
31–40 152 36 (23.7%)
41–50 164 33 (20.1%)
$51 341 63 (18.5%)
doi:10.1371/journal.pone.0009126.t004
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anti-ZEBOV IgG was mainly directed to the viral proteins NP,
VP40, VP35 and sGP. These results, together with the high
seroprevalence rates and ELISA positivity on highly diluted sera,
support the specificity of the observed IgG reactivity. They thus
imply that IgG antibodies were generated in response to ZEBOV
exposure of the individuals concerned. In order to rule out false-
positive antibody responses, we further investigated ZEBOV-
specific T cell memory responses in seven randomly selected IgG+
individuals. Despite inter-individual variability, we observed
higher IFN-c production in CD8+ T cells from IgG+ individuals
than in negative controls, a finding indicative of memory T cell
responses to ZEBOV. It is now well recognized that CD8 T cell
responses to acute viral infection can be divided into three distinct
phases [37–40]. Antigenic stimulation leads to massive clonal
expansion of naı ¨ve CD8 T cells and to the acquisition of effector
functions, including IFN-c and TNF-a production and cytotoxic
activity that render the cells capable of killing virus-infected cells.
Once the infection is resolved, 90–95% of activated effector CD8
T cells die through apoptosis, while the remainder form a long-
lived population of memory cells. Memory CD8 T cells have an
enhanced capacity to control secondary antigen exposure, through
more efficient proliferation, rapid acquisition of effector functions,
IFN-c and TNF-a production, and migration to peripheral sites of
infection [41]. Long-term protective memory after initial antigen
exposure has been shown in individuals vaccinated against the
viruses causing smallpox, yellow fever, measles and polio [42].
Memory CD8 T cell responses can persist for up to 75 years after
vaccination, thus providing lifelong protection [43]. Furthermore,
a recent study showed that 90% of individuals vaccinated against
smallpox still had vaccinia virus-specific IFN-c-producing CD8 T
cells, indicating that long-term protection is mediated by memory
CD8 T cell responses [44,45]. Highly effective protection of
experimental rodents and non human primates against Ebola virus
infection after various types of vaccination is associated with the
generation of ZEBOV-specific IFN-c-producing CD8 T cells and
antibody responses [46–52]. Consequently, the detection of both
ZEBOV-specific IgG and IFN-c-producing CD8 T cell responses
in all the healthy seropositive individuals tested here shows that
these individuals must have been exposed to ZEBOV. Although
EHF is not always associated with bleeding, other symptoms
(abrupt-onset high fever, severe diarrhea and vomiting, breast and
chest pain, etc.) are frequently severe and are therefore easily
remembered. Furthermore, even if bleeding does not occur, severe
forms of ZEBOV infections are associated with high viral load in
other body fluids and, therefore, with high infectivity, inducing
human-to-human transmission and secondary cases. Such events
are unlikely to go undetected in Gabon. For these reasons, we
believe most of the seropositive persons identified in our survey
had probably had mild or asymptomatic infection, or were simply
exposed to viral particles.
The similar rates of EBOV seropositivity in non epidemic
regions and outbreak areas of Gabon, together with the small
number of survivors from past outbreaks, rule out an important
role of human-to-human transmission and rather suggest direct or
indirect contact with infected animals. Moreover importantly,
ZEBOV is mainly excreted in blood, diarrhea and vomit. ZEBOV
is present in very large amounts in these fluids (more than several
million virions per mL) during the acute phase of the disease.
Although viral particles have been detected in saliva and sweat
from acutely ill patients, human-human transmission by this route
has not been documented. This putative transmission route would
be even more unlikely in the case of mild or asymptomatic disease
which is associated with a much lower viral load. Only three
animal species, in addition to humans, have been shown to be
naturally infected by ZEBOV. Chimpanzees and gorillas are
unlikely candidates, as infection occurs only occasionally and
death ensues rapidly [16,23,24]. Moreover, wild populations are
small and live deep in the forest far from villages, while physical
contacts with humans are rare and generally involve dead
carcasses.
Fruit bat species (Hypsignathus monstrosus, Epomops franqueti and
Myonycteris torquata) are naturally infected by ZEBOV, suggesting
they may act as natural reservoirs [18,19]. All three bat species
have broad geographical ranges that are known to include the
entire tropical forest regions of equatorial central Africa [53].
These bat populations are particularly abundant in the forested
areas of Gabon, where ZEBOV-specific seroprevalence rates are
high compared to Lakeland and Savannah areas, that themselves
harbor other species of bats [53]. Moreover, these bats roost in
massive numbers on trees and consume their fruits, especially
within and around villages. Thus, it is possible that ZEBOV
antigenic stimulation or aborted infection could occur when
villagers handle and eat fruits which have been contaminated by
bat saliva that may contain infectious virus, inactivated virus, or
simple viral antigens. Brief contact with non infectious viral
particles is sufficient to induce the type of specific immunity
observed in our study. Indeed, CD4+ and CD8+ T cells are
capable of activating and proliferating after a short encounter with
an antigen, without the need for continued antigenic stimulation
[54]. Gender, hunting activity and contact with animals did not
appear to influence the risk of IgG seropositivity in our study. It is
noteworthy that small children are less exposed to potentially
contaminated fruit, and that ZEBOV seropositivity increased
linearly with age during childhood. These routes of infection have
been strongly implicated in pig infection by nipah virus and horse
infection by hendra virus, both viruses belonging to the
Paramyxoviridae family [55,56], another family of Mononegavirales
(enveloped single-stranded viruses with an RNA monosegmented
genome of negative polarity and capsids with helical symmetry).
This study provides important insights into ZEBOV circulation,
human exposure and pathogenicity, and outbreak occurrence. In
particular, we found a strikingly high proportion of individuals
living in forested areas of Gabon who had both specific humoral
and cellular immunity to ZEBOV. The high frequency of
‘immune’ individuals with no disease or outbreak history raises
questions as to the real pathogenicity of ZEBOV for humans in
‘natural’ conditions. Added to the lack of identifiable risk factors,
this points to bats as the main source of human exposure, through
Figure 4. Western blot analysis of ZEBOV-specific IgG from two
symptomatic individuals who recovered (T+), one negative
endemic control, and 10 IgG+ asymptomatic individuals.
doi:10.1371/journal.pone.0009126.g004
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which no animal source was identified may have been due to fruit
bat activity close to the villages concerned. Rural populations
living in forested regions of the central African forest block thus
appear to be highly exposed to the virus. More and more viruses
are being detected in bats, some of which are known to be
pathogenic for humans.
Materials and Methods
Study Area and Population
The survey was conducted in Gabon, Central Africa. Nearly
80% of Gabon is covered by rain forest, which is subdivided into
three different types, from North-East to South-West of the
country [57]: the northern-eastern forest located near Cameroon
and the Republic of Congo, the interior forest (characterized
mainly by the presence of Okoume trees), and the mountain forest.
Gabon also has a grassland region located between the coastline
and mountain forest, as well as a dry savannah located mainly in
the south-east, south-west and center, and a wide ‘‘Lakeland’’ and
long coastline to the west (Figure 1). Gabon has a surface area of
267,667 km
2 and is divided into nine administrative regions
comprising a total of 2,048 villages, most of which are located
along roads (Figure 1). Few villages have more than 300
inhabitants.
The current serosurvey was conducted by a multidisciplinary
team, including a doctor from the Gabonese Ministry of Health, a
nurse, an epidemiologist, a virologist, a veterinarian and
laboratory technicians. It focused on rural villages with fewer
than 300 inhabitants located in the nine administrative regions of
Gabon. It took place during nine one-month field missions,
between 2005 and 2008. The survey covered 220 randomly
selected villages (Figure 1), representing 10.7% of all villages in
Gabon. The traditional chiefs of each village were first informed of
Figure 5. ZEBOV-specific memory T cell analysis by flow cytometry. IFN-c production by CD3+CD8+ T lymphocytes was evaluated by
intracellular flow cytometry on PBMC stimulated with mock supernatant (green histograms) or heat-inactivated ZEBOV culture supernatant (iZEBOV,
red histograms). Analysis performed 2 and 3 days after stimulation of PBMC from seven IgG+ asymptomatic individuals (A), four negative controls
and three laboratory-confirmed survivors of the 2001–2002 outbreak in Gabon (B). No significant responses were observed in CD4+ T lymphocytes.
doi:10.1371/journal.pone.0009126.g005
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villagers. All inhabitants aged $16 years were eligible for the study.
The study was described orally, and volunteers gave their signed
informed consent to be enrolled in the study and for their blood
samples to be used for future research studies. Each participant
answered an anonymous oral questionnaire that included questions
on demographics, lifestyle, work, social activities, diet and past
medical illness. Villages were randomly selected in each of the nine
provinces. We then randomly selected around 10% of the villages in
each province, regardless of their size (50 to 300 persons). We
systematically excluded children, elderly persons (more than ,65
years), persons who were not permanent residents in the villages,
and those who had been permanent residents for less than a year.
Some inhabitants were not present at the time of our visit, because
of their daily activities. In view of all these factors, the number of
persons who refused was quite low (around 15% of the eligible
population), representing 12 to 97 persons per village. This is
unlikely to have had a significant impact on the results. A free
medical examination and basic medicines were proposed to all
participants and non participants. The samples were obtained after
the interview. A total of 4,349 persons were enrolled.
In addition, we conducted a specific field mission to enroll
laboratory-confirmed survivors of the three Gabonese ZEBOV
outbreaks. After three months of investigations throughout the
outbreak areas of Ogooue ´ Ivindo region between June and August
2007, 20 survivors of the 2001 Mekambo, 1996 Booue ´ and 1996
Mayibout outbreaks were identified and enrolled.
Finally, another specific field mission was carried out to enroll
children aged 15 years or less. In total, 395 children aged between
2 and 15 years were randomly selected in six villages located in the
northern-eastern forest region (Figure 1). In addition to a free
medical examination and basic medicines, all children in each
village had blood smears for malaria diagnosis and blood typing in
the field. The results were given the following day and antimalarial
drugs were provided if appropriate.
The two study protocols were reviewed and approved together
by the Gabonese Ministry of Health (authorization nu00093/
MSP/SG/SGAQM). Written consent was obtained from the
Health Director of each region, the traditional chiefs of each
village, and all participants. The parents’ written consent was
obtained for participating children.
Blood Collection
A total of 4,349 blood samples were collected, usually in the
villages’ local healthcare centers. Our team was located in the
main town of each administrative region, and field laboratory
facilities were set up interior the General Hospital. Blood samples
were collected in the villages on a daily basis, into two 7-ml
Vacutainer tubes containing EDTA (VWR International, France).
The tubes were then transported to the field lab, and plasma was
obtained by centrifugation each evening. Plasma samples were
kept at 220uC until the end of the field mission, then transported
to Centre International de Recherches Me ´dicales de Franceville
(CIRMF), Gabon, and stored at 280uC until use.
Peripheral blood mononuclear cells (PBMC) were collected
from 200 randomly selected individuals from among the 4,349
participants, and from the 20 survivors (see above). PBMC were
separated from whole blood by density gradient centrifugation on
lymphocyte separation medium (Eurobio) at 2,300 rpm for 20 min
at room temperature. PBMC were then washed with phosphate
buffered saline (PBS)-2% fetal calf serum (FCS), and were
cryopreserved in FCS containing 10% DMSO in dry nitrogen
until being transported to CIRMF. PBMC were finally stored at
CIRMF in liquid nitrogen until immunological analysis.
ZEBOV-Specific IgG Detection
An IgG ELISA method was used as previously described [27],
with antigens kindly provided by the Special Pathogens Branch,
Centers for Disease Control (Atlanta, USA). Briefly, Maxisorp
plates (Nunc, Denmark) were coated with ZEBOV antigens diluted
1:1000 in PBS, overnight at +4uC. Control plates were coated with
uninfected Vero cell culture antigens in the same conditions. Sera
were diluted 1:1600 in 5% non fat milk in PBS-Tween 20 (0.1%)
and incubated in the wells overnight at +4uC. Binding was
visualized by using a peroxidase-labeled antibody to human IgG
(Sigma, France) and the TMB detector system (Dynex Technolo-
gies, France). Optical density was measured at 450 nm with an
ELISA plate reader. For each sample, we calculated the corrected
optical density (OD) as the optical density of the antigen-coated well
minus the OD of the corresponding control well.
A panel of 104 sera from individuals who had never visited
Africa was obtained from Marseille, France, and used as negative
controls for cut-off calculation.
Western Blot
ZEBOV antigens were kindly provided by Dr. V.E. Volchkov
(Laboratoire P4 Jean Me ´rieux, Lyon, France). They were separated on
10% NuPAGE Bis-Tris acrylamide gel (Invitrogen, UK) and
transferred to nitrocellulose membranes for 1 hour at 30 V. The
membranes were blocked overnight at 4uCi nP B S ,5 %n o n f a tm i l k ,
and 0.1% Tween 20. The test sera were diluted 1:100 in PBS, 2.5%
milk, 0.1% Tween, and incubated with the membrane for 2 hours at
room temperature. The membrane was then incubated with HRP-
conjugated goat anti-human IgG (H+L) (P.A.R.I.S., France) diluted
1:5000 in PBS 2.5% milk, 0.1% Tween 20. Bound antibodies were
visualized with a chemiluminescent substrate, following the manufac-
turer’s protocol (Pierce, France). Three washes in PBS 0.1% Tween 20
were performed after blocking and each incubation step.
Virus Titration
The virus used in this study belonged to Zaire ebolavirus lineage B
and was isolated from the plasma of a patient who died during the
Figure 6. ZEBOV-specific memory T cell analysis by flow
cytometry. IFN-c production by CD8+ T lymphocytes was evaluated
by intracellular flow cytometry on PBMC stimulated with mock
supernatant (green histograms) or heat-inactivated ZEBOV culture
supernatant (iZEBOV, red histograms). Analyses performed 2, 3, 5 and 7
days after initial iZEBOV or mock stimulation (arrow) of PBMC from
three IgG+ asymptomatic individuals. A second round of stimulation
was performed on day 6. Results for one IgG+ individual are shown.
doi:10.1371/journal.pone.0009126.g006
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monolayers of Vero E6 cells in 25-cm
2 plastic tissue culture flasks.
The cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM, Life Technologies, France) supplemented with 2% heat-
inactivated FCS, penicillin 10 U/ml and streptomycin 10 mg/ml
(Invitrogen) at +37uC with 5% CO2. The virus stock was prepared
from the supernatant of infected Vero E6 cells after two passages
(Vero E6+2).
The ZEBOV stock was titered using a modified conventional
plaque assay [58]. Serial 10-fold dilutions of 250 mLo f
supernatant were incubated in DMEM-2% heat-inactivated
FCS for 1 h at 37uCo nV e r oE 6c e l l sg r o w nt oc o n f l u e n c ei n6 -
well plastic tissue culture plates. Two milliliters of 1.6%
carboxymethyl cellulose (BDH Laboratories, Poole, United
Kingdom) in complete DMEM-2% FCS were then added to
each well, and the plates were incubated at 37uCw i t h5 %C O 2
for 5 days. The cells were fixed with 4% formaldehyde (Sigma,
Courtaboeuf, France) in PBS, washed, and permeabilized with
0.5% Triton X-100 (Sigma) in PBS. A mix of monoclonal
antibodies specific for ZEBOV GP, NP, VP40 and VP35, kindly
provided by Dr. S. Baize (Laboratoire P4 Jean Me ´rieux, Lyon,
France), was then added overnight at +4uC. A peroxidase-
conjugated goat anti-mouse antibody diluted 1:1600 (Sigma)
was then added for 1 h at 37uC ,a n df o c io fi n f e c t e dc e l l sw e r e
revealed with diaminobenzidine (Sigma).
All infections were performed in BSL-4 conditions at CIRMF
(glove box model). ZEBOV-infected supernatants were removed
in BSL-4 conditions and heat-inactivated at 56uC for 40 min.
Inactivated ZEBOV (iZEBOV) was stored at 280uC until use.
PBMC Culture and Antigenic Stimulation
Cryopreserved PBMC were rapidly thawed in a 37uC water
bath, washed twice and incubated overnight at 37uC in RPMI
1640 culture medium (Life technologies, UK) with 10% heat-
inactivated FCS (full RPMI-10% FCS), 1% penicillin-streptomy-
cin, 1% nonessential amino acids, and 1 M HEPES. PBMC were
then washed in RPMI medium, adjusted to a density of
1610
6 cells/mL, and cultured in 24-well flat-bottom culture
plates. Cells were immediately stimulated with inactivated ZEBV
(iZEBOV) at a multiplicity of infection (MOI) of 1. Three samples
containing enough PBMC were again stimulated with iZEBOV at
MOI 1 on day 5 (Figure 4). Interleukin-2 (Becton Dickinson,
France) was added to the cells on day 2 after stimulation with
iZEBOV (PI) at a final concentration of 100 U/mL. Negative
controls included cells stimulated with an equal volume of
uninfected Vero E6 supernatant (mock), and positive controls
included cells stimulated with phytohemagglutinin A (PHA, 3 mg/
mL final).
PBMC Phenotyping and Intracellular Cytokine Staining
PBMC from seven individuals were analyzed on days 2 and 3
after iZEBOV stimulation, and PBMC from three of these
individuals were also analyzed on days 5 and 7. PBMC were
incubated for 5 hours with 10 mg/mL Brefeldin A (Sigma) and
2 mM monensin (Sigma), then harvested and washed in culture
medium. Approximately 0.5610
6 cells were labeled for 20 min at
room temperature with monoclonal antibodies (Beckman-Coulter,
Geneva, Switzerland): PC5-conjugated anti-human CD3, PC7-
conjugated anti-CD4 and PC7-conjugated anti-CD8. Isotype
controls consisted of cells labeled with FITC-conjugated mouse
IgG1 and PE-conjugated IgG1 (Beckman-Coulter). Cells were
then fixed and permeabilized with IntraPrep reagent (Beckman-
Coulter) as recommended by the manufacturer. Permeabilized
cells were labeled for 20 min at room temperature with FITC-
conjugated anti-IFN-c and PE-conjugated anti-TNF-a (Beckman-
Coulter). Cells were then washed, resuspended in 2% FCS, and
analyzed with an FC500 four-color flow cytometer (Beckman
Coulter) and CXP software (Beckman Coulter).
Statistical Methods
All statistical analyses were performed using STATA software
version 10 (STATA Corporation, College Station, Texas, USA).
Overall and subgroup-specific ZEBOV seroprevalence rates were
estimated and potential differences between subgroups were
evaluated by using binomial survey-adjusted chi-square tests.
Significance was assumed at p #0.01.
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